Aglatimagene besadenovec

Aglatimagene besadenovec (CAN-2409) is a gene therapy developed by Candel Therapeutics. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. The sponsor states: An adenovirus-based immunotherapy (AdV-tk/CAN-2409) that blocks DNA synthesis in dividing tumour cells, causing tumour cell death, while adenovirus capsid proteins attract immune cells to the tumour microenvironment so activated immune cells can then attack distant metastases. ClinicalTrials.gov describes the intervention as: Aglatimagene besadenovec will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second aglatimagene besadenovec injection will be 2-3 weeks after the first follo. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07660094 (Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)), in non-small-cell lung cancer and prostate cancer. The largest, NCT07660094, plans to enrol 500 participants with primary completion expected 2031-10-22. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.